Moomoo AIのまとめ
An amendment to Schedule 13G has been filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a change in their holdings of ZyVersa Therapeutics, Inc. common stock. The filing, dated September 30, 2024, reports that these entities and individuals collectively own 54,054 shares, representing 4.9% of the company's issued common stock. This stake is held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors, with the power to direct voting and disposition of the shares. The amendment restates the previously filed Schedule 13G and provides updated information on the beneficial ownership, including the address and organizational details of the reporting persons. The filing also certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.
An amendment to Schedule 13G has been filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a change in their holdings of ZyVersa Therapeutics, Inc. common stock. The filing, dated September 30, 2024, reports that these entities and individuals collectively own 54,054 shares, representing 4.9% of the company's issued common stock. This stake is held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors, with the power to direct voting and disposition of the shares. The amendment restates the previously filed Schedule 13G and provides updated information on the beneficial ownership, including the address and organizational details of the reporting persons. The filing also certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.
Anson Funds Management LP、Anson Management GP LLC、Tony Moore、Anson Advisors Inc.、Amin Nathoo、Moez Kassamによって、ZyVersa Therapeutics, Inc.の普通株式の保有状況に変更があることを示すSchedule 13Gの改正がSECに提出されました。この提出日は2024年9月30日で、これらの法人および個人は合計で54,054株を保有しており、これは会社の発行済み普通株式の4.9%に相当します。この持分は、Anson Funds Management LPとAnson Advi...すべて展開
Anson Funds Management LP、Anson Management GP LLC、Tony Moore、Anson Advisors Inc.、Amin Nathoo、Moez Kassamによって、ZyVersa Therapeutics, Inc.の普通株式の保有状況に変更があることを示すSchedule 13Gの改正がSECに提出されました。この提出日は2024年9月30日で、これらの法人および個人は合計で54,054株を保有しており、これは会社の発行済み普通株式の4.9%に相当します。この持分は、Anson Funds Management LPとAnson Advisors Inc.が共同投資アドバイザーとして、株式の投票および処分の権限を持つプライベートファンドによって保有されています。この改正は、以前に提出されたSchedule 13Gを再記載し、報告者の住所や組織の詳細を含む利益所有権に関する最新情報を提供します。この提出は、これらの株式がビジネスの通常の過程で取得されたものであり、ZyVersa Therapeutics, Inc.の支配を変更または影響を与える目的で取得されたものでないことを証明しています。
役に立った
役に立たない
この開示の添付ファイルは以下です：
